GlassScriptPhysician profile
Trang D Lusk
NPI 1437345675
$6,218.65
in general payments reported to CMS, 2019-2025
29 companies · $489 in 2025
The $489 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,799 · 2022: $1,457 · 2023: $1,300 · 2024: $1,175 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,963.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $890.16 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $730.97 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $637.33 | 2021-2025 | Ozempic, Rybelsus, Tresiba |
| Astrazeneca Pharmaceuticals LP | $621.22 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $420.90 | 2021-2025 | |
| Dexcom, INC. | $352.03 | 2021-2023 | Dexcom G7 Gss (161) |
| Amgen INC. | $295.23 | 2021-2024 | Otezla, Repatha, Krystexxa |
| Janssen Pharmaceuticals, INC | $270.98 | 2021-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.73 | 2021-2023 | Tradjenta, Synjardy |
| Pfizer INC. | $224.31 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $178.25 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $177.36 | 2021-2024 | |
| Abbott Laboratories | $158.31 | 2021-2023 | Freestyle Libre 3 |
| Nestle Healthcare Nutrition INC. | $157.36 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $146.63 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $129.68 | 2023-2024 | Gvoke Hypopen |
| Exact Sciences Corporation | $118.79 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $69.83 | 2021-2024 | Rexulti |
| Daiichi Sankyo INC. | $64.38 | 2021-2024 | Injectafer |
| Paratek Pharmaceuticals, INC. | $64.17 | 2021-2022 | |
| Esperion Therapeutics, INC. | $50.85 | 2021 | |
| Eisai INC. | $50.20 | 2021-2024 | |
| Astellas Pharma US INC | $42.75 | 2021-2023 | Veozah |
| Idorsia Pharmaceuticals US INC | $34.17 | 2022-2024 | Quviviq |
| Merck Sharp & Dohme LLC | $33.80 | 2021 | |
| Lucid Diagnostics INC. | $20.44 | 2024 | |
| Boston Scientific Corporation | $17.66 | 2021 | |
| Hikma Pharmaceuticals USA | $15.56 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trang Lusk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.